On Sept. 19, 2014, the Centers for Disease Control and Prevention”s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13) among adults aged =65 years.

PCV13 should be administered in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax23, Merck & Co.]), the vaccine was recommended for adults aged =65 years. PCV13 was approved by the FDA in late 2011 for use among adults aged =50 years.